Pharma: Innovative Assays for Immunotherapy Drug Discovery Programs
Tools and Emerging Areas
Immunotherapy is a powerful tool in the targeted treatment of a wide range of disease pathologies and the number of immunotherapy drugs in the discovery pipeline continues to grow. Approaches can include switching off or restoring balance to aberrant immune responses (such as those in autoimmune disease or allergy) or switching on beneficial immune responses (such as those that can drive in tumour cell clearance in cancer).
In addition to showcasing innovative in vitro assays for immunotherapy drug discovery, this webinar will also summarise the current challenges, considerations, and emerging areas within the field. There will also be a live Q&A session where you’ll be able to put your questions to our expert..
Rhoanne McPherson,
Rhoanne McPherson is a Principal Scientist at Concept Life Sciences, which is based at Edinburgh’s BioQuarter campus. After obtaining a PhD from the University of Edinburgh in 2012, she spent several years as a post-doctoral scientist focussing on mechanisms of immune pathology and potential therapeutic interventions. Throughout these roles, Rhoanne built expertise the role of checkpoint inhibitors in inducing and maintaining T cell tolerance. In 2017 She moved to Concept Life Sciences (formerly Aquila BioMedical), where her main areas of focus are immuno-oncology and autoimmune inflammation and she is actively involved in further developing Concept’s innovative platform of in vitro and in vivo assays to assist and accelerate immunotherapy drug discovery.
Biomarker Development Specialist